Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.37 |
| ▸ | BRD4 | O60885 | 4/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.35 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.34 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.34 |
| ▸ | PDE1A | P54750 | 1/20 | 0.33 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12409687 | 0.83 | PIK3C3 (0.38) | CNR2MAP3K5BRD4GRM2PIK3C3 | |
| SCHEMBL2287748 | 0.80 | PIK3C3 (0.40) | KMT2ABRD4GRM2ALDH1A1PIK3C3 | |
| SCHEMBL2278273 | 0.79 | BRD4 (0.39) | BRD4GRM2PIK3C3PDE1CPDE1A | |
| SCHEMBL12376643 | 0.76 | MEN1 (0.61) | MEN1KMT2ABRD4ALDH1A1 | |
| SCHEMBL13101593 | 0.75 | ALDH1A1 (0.39) | CNR2MEN1KMT2AALDH1A1CNR1 | |
| SCHEMBL13101591 | 0.74 | ALDH1A1 (0.44) | MEN1KMT2AALDH1A1 | |
| SCHEMBL27778069 | 0.69 | BRD4 (0.40) | BRD4GRM2PIK3C3PDE1CPDE1A | |
| SCHEMBL27778071 | 0.69 | GRM2 (0.40) | BRD4GRM2PDE1CPDE1APDE1B | |
| SCHEMBL12376648 | 0.68 | RIPK1 (0.50) | MEN1KMT2AALDH1A1 | |
| SCHEMBL13101595 | 0.68 | RIPK1 (0.41) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003662-B2 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ERBB2, LCK, SRC | CNR2 482/4885MEN1 3149/4885KMT2A 4415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.